Hansoh files China's first domestic TYK2 inhibitor NDA as four local Phase 3 rivals converge
Hansoh Pharmaceutical (HKEX: 03692) won NMPA NDA acceptance on Nov 20, 2026 for TYK2 inhibitor socrodeucitinib (HS-10374, CXHS2600155/156) in plaque psoriasis 60 days after its Phase 3 readout.
Hansoh Pharmaceutical Group (HKEX: 03692) disclosed on November 20, 2026 that China’s National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for its self-developed oral selective tyrosine kinase 2 (TYK2) allosteric inhibitor socrodeucitinib (HS-10374, Center for Drug Evaluation (CDE) acceptance numbers CXHS2600155 and CXHS2600156) for adult patients with moderate-to-severe plaque psoriasis. While four Chinese-originated TYK2 inhibitors reported positive Phase 3 psoriasis readouts during 2026, Hansoh converted its September 21 Phase 3 top-line readout into a formal NDA acceptance in exactly 60 calendar days—overtaking InnoCare Pharma (HKEX: 09969; SSE: 688428), which announced positive Phase 3 data for fadeucravacitinib (ICP-488) two months earlier in July 2026, and securing the first domestic NDA slot behind Bristol Myers Squibb’s (NYSE: BMY) marketed Sotyktu (deucravacitinib).
The filing extends Hansoh’s rapid build-out in oral autoimmune dermatology just nine days after its RMB 317 million AI-driven oral macrocyclic peptide discovery collaboration with AilsynBio, while setting up a direct commercial versus clinical-efficacy clash against InventisBio’s (SSE: 688382) nomelcitinib (D-2570), which reported >70% Week 16 PASI 90 clearance on November 2.
Speed to filing versus numerical PASI 90 clearance across six TYK2 programs
Selective TYK2 inhibitors bind the regulatory pseudokinase (JH2) domain rather than the catalytic (JH1) domain conserved across JAK1, JAK2, and JAK3, blocking IL-23, IL-12, and Type I interferon signaling without triggering the lipid, hematologic, and cardiovascular boxed warnings attached to pan-JAK inhibitors. However, BMS’s first-in-class Sotyktu (6 mg QD, approved in China in October 2023 and already listed on the National Reimbursement Drug List (NRDL)) left a wide efficacy gap between oral therapy (Week 16 PASI 90 of ~35.5% and PASI 100 of ~14.2% in POETYK PSO-1) and injectable IL-17/IL-23 biologics.
Next-generation global and Chinese JH2 allosteric inhibitors were engineered to close that clearance gap by increasing TYK2 residence time and exposure:
| Drug & Codes | Originator / Partner (Ticker) |
Phase 3 Psoriasis Efficacy (Week 16 unless noted) |
Key Phase 2 Reference Data (Week 12) |
Regulatory Status (as of Nov 21, 2026) |
|---|---|---|---|---|
socrodeucitinib (HS-10374) |
Hansoh Pharma (03692.HK) (wholly owned) |
Met co-primary PASI 75 & sPGA 0/1; PASI 90 >50%, PASI 100 ~33% (Sept 21, 2026 readout) |
NCT06077331 (12 mg QD): PASI 75 72.1%, PASI 90 46.5% vs. 0% placebo |
China NMPA NDA accepted Nov 20, 2026 (CXHS2600155 / CXHS2600156) — 1st domestic TYK2 NDA |
nomelcitinib (D-2570) |
InventisBio (688382.SS) (wholly owned) |
Met co-primaries (n=391, 1:1:1); PASI 90 >70% and PGA 0/1 >80% across both active dose arms (Nov 2, 2026 readout) |
NCT06278350 (3 QD doses): PASI 75 85.0%–90.0%, PASI 90 70.7%–77.5%, PASI 100 39.0%–50.0% |
China NDA preparation underway; running separate China Phase 3 head-to-head vs. Sotyktu + U.S. Ph2 |
fadeucravacitinib (ICP-488) |
InnoCare Pharma (09969.HK / 688428.SS) (wholly owned) |
Met co-primary PASI 75 & sPGA 0/1 (July 2026 readout; exact Phase 3 PASI 90 % undisclosed) |
NCT06109818 (n=129, 9 mg QD): PASI 75 78.6%, PASI 90 50.0%, PASI 100 11.9%, sPGA 0/1 71.4% |
China NDA submission pending (overtaken by Hansoh despite 2-month earlier Ph3 readout) |
envudeucitinib (ESK-001) |
Haisco (002653.SZ) / Alumis (NASDAQ: ALMS) ($60m upfront + $120m milestones; Kaken Japan $180m deal) |
ONWARD1 & ONWARD2 (Mar 2026): Week 16 PASI 90 59.9% & 53.1% (Week 24: 68.0% & 62.1%; ONWARD3 Week 48 n=773: PASI 90 75%, PASI 100 54%) |
STRIDE (NCT05600036, 40 mg BID): PASI 75 64.1%, PASI 90 38.5%, PASI 100 15.4% |
U.S. FDA NDA submission targeted for Q4 2026 |
zasocitinib (TAK-279) |
Nimbus / Takeda (4502.T / TAK, $4.0b upfront) |
LATITUDE Ph3 & LATITUDE Atlas (n=606, June 2026): Superior to Sotyktu head-to-head; PASI 100 >35% vs. <14% at Week 16 |
NCT04999839 (30 mg QD): PASI 75 67%, PASI 90 46%, PASI 100 33% |
U.S. FDA NDA submitted Sept 2026 (decision expected 2027); China Ph3 ongoing |
deucravacitinib (Sotyktu) |
Bristol Myers Squibb (NYSE: BMY) |
POETYK PSO-1 (6 mg QD): Week 16 PASI 75 58.4%, PASI 90 35.5%, PASI 100 14.2% |
First-in-class deuterated JH2 reference benchmark |
Approved (U.S. Sept 2022; China Oct 2023; included on China NRDL) |
Why Hansoh’s 60-day regulatory sprint matters
Across the domestic cohort, clinical differentiation splits sharply between execution speed and peak skin clearance. By pushing socrodeucitinib (HS-10374) from top-line data (September 21) to NMPA NDA acceptance (November 20) in two months, Hansoh positioned itself for potential China marketing approval in H1 2028—establishing a first-mover commercial window among domestic TYK2 entrants and lining up for the 2028 NRDL negotiation cycle. Its Week 16 profile (>50% PASI 90 and ~33% PASI 100) roughly doubles Sotyktu’s complete-clearance rate and matches Takeda’s zasocitinib (TAK-279).
However, Hansoh will not hold an uncontested efficacy lead for long. InventisBio’s nomelcitinib (D-2570) posted >70% Week 16 PASI 90 across 391 Phase 3 patients on November 2—matching injectable anti-IL-17/IL-23 biologics and Haisco’s (002653.SZ) newly registered oral IL-23 inhibitor HSK47388—and is already running a dedicated head-to-head China Phase 3 trial against Sotyktu.
Next evidence triggers to watch
CDENDAacceptance numbers forICP-488andD-2570(Q4 2026 – Q1 2027): Whether InnoCare (09969.HK) and InventisBio (688382.SS) file their ChinaNDAsbefore year-end 2026, determining how many months of domestic commercial exclusivityHS-10374captures.- Full Phase 3 dataset disclosures at 2027 dermatology congresses (
AAD 2027/EADV): Complete dose-by-dosePASI 75/90/100tables,CPKelevation, acne/folliculitis, and herpes zoster rates forHS-10374versusD-2570andICP-488, alongside any ex-China out-licensing transaction forD-2570orHS-10374.